Invasive fungal infections – Page 2

Improving the production of micafungin precursor FR901379 in Coleophoma empetri using heavy-ion irradiation and its mechanism analysis

mycolabadmin

Researchers used heavy-ion radiation to create improved strains of a fungus that produces a precursor to micafungin, an important antifungal drug. The improved strains produced over 3.5 times more of the desired compound than the original strain. By analyzing the genetic changes in these improved strains, the scientists identified which genes were most important for boosting production, helping guide future improvements in manufacturing this life-saving medicine.

Characterization of the Spatiotemporal Localization of a Pan-Mucorales–Specific Antigen During Germination and Immunohistochemistry

mycolabadmin

Researchers developed a test using a special antibody (TG11) that can specifically identify dangerous mold infections (mucormycosis) in tissue samples. The antibody glows when it finds the molds at early stages of growth, even when they first start germinating. Unlike other diagnostic methods, this antibody can tell the difference between dangerous Mucorales molds and other common molds like Aspergillus, which is important for doctors to give the right treatment quickly.

Transcriptomics Insights into Targeting CK2 Complex in Cryptococcus neoformans: Implications for Large-Scale Antifungal Virtual Screening

mycolabadmin

Scientists studied how a fungus called Cryptococcus neoformans causes serious brain infections and found that disabling a specific protein complex (CK2) could be an effective treatment strategy. Using computer analysis of genetic data, they identified three existing drugs—amphotericin B, idarubicin, and candicidin—that could potentially target and kill this dangerous fungus. This research provides a foundation for developing better treatments for cryptococcal meningitis, a life-threatening infection that kills hundreds of thousands of people annually, especially those with weakened immune systems.

Clinical aspects and recent advances in fungal diseases impacting human health

mycolabadmin

Fungal infections are increasingly common health threats affecting over a billion people worldwide, ranging from minor allergies to serious life-threatening infections. The biggest problems are that fungi are becoming resistant to current medications, diagnosis can be difficult and slow, and treatment options are limited. Recent developments include new antifungal drugs like ibrexafungerp and rezafungin that work differently from older medications, offering hope for treating resistant infections. Better awareness among doctors and patients, faster diagnostic methods, and responsible use of antifungals are essential to combat this growing public health challenge.

Fungal β-Glucans: Biological Properties, Immunomodulatory Effects, Diagnostic and Therapeutic Applications

mycolabadmin

β-glucans are beneficial compounds found in fungi and some plants that help your body in multiple ways. They boost your immune system, lower cholesterol and blood sugar, protect against oxidative stress, and may help fight cancer and infections. Recent research shows they could be useful as diagnostic markers for fungal infections and as vaccine boosters, especially for diseases like COVID-19.

Prevalence and antifungal susceptibility profiles of Candida isolates among patients with candiduria: a multiplex PCR assay

mycolabadmin

This study examined Candida yeast infections in urine samples from hospitalized patients in Iran. Researchers identified seven different Candida species using a specialized PCR test and tested how well they responded to three antifungal medications. They found that while Candida albicans was most common, other species showed much higher resistance to fluconazole treatment. The findings highlight the importance of proper species identification for choosing the right treatment.

Breakthrough Invasive Mould Infections Under Posaconazole Prophylaxis in Patients With Haematologic Malignancies: A Case–Control Study

mycolabadmin

This study examined cases where patients receiving posaconazole to prevent fungal infections still developed serious mould infections despite the medication. Researchers compared 29 patients who developed these breakthrough infections with 46 control patients who did not. They found that over half of patients with breakthrough infections died, compared to only 20% of controls, and that surgical treatment significantly improved survival for certain types of fungal infections.

Invasive Fungal Infections in Orthotopic Heart Transplant Patients: Incidence and Risk Factors in the Modern Era

mycolabadmin

This study examined fungal infections in heart transplant patients at Cleveland Clinic between 2010-2020. Researchers found that about 5% of heart transplant patients developed serious fungal infections, with Candida being the most common culprit. Patients with previous fungal infections, those who needed additional surgeries after transplant, and those requiring life support machines (ECMO) had the highest risk. Heart transplant patients with fungal infections had much worse survival rates, suggesting the need for better prevention strategies using antifungal medications.

Drug repurposing to fight resistant fungal species: Recent developments as novel therapeutic strategies

mycolabadmin

Fungal infections are becoming increasingly difficult to treat due to growing drug resistance, affecting millions of people worldwide each year. This research collection explores creative solutions by repurposing existing medications and developing new combination therapies that work better together against resistant fungal species. Studies show promising results combining common antibiotics like minocycline with antifungal drugs, and natural compounds from traditional medicine show potential for treating hard-to-treat infections like Candida and Aspergillus.

Aspergillus fumigatus dsRNA virus promotes fungal fitness and pathogenicity in the mammalian host

mycolabadmin

A virus that infects the fungus Aspergillus fumigatus makes the fungus more dangerous by helping it survive stress and resist immune cell attack. When researchers removed the virus from the fungus, it became weaker and less harmful to infected mice. Treating infected mice with an antiviral drug called ribavirin reduced the virus, lowering fungal burden and improving survival, suggesting that targeting fungal viruses could be a new way to treat serious fungal infections.

Disease: Invasive fungal infections